期刊文献+

结肠癌KRAS基因突变与病理特征、吸烟和饮酒的相关性 被引量:2

Correlation between KRAS Gene Mutations of CRC and Pathological Features,Smoking and Alcohol Drinking
下载PDF
导出
摘要 目的探讨结肠癌(CRC)组织KRAS基因突变情况并分析其与CRC病理特征、吸烟和饮酒的相关性。方法采用ARMS-PCR法检测82例CRC患者癌组织KRAS基因外显子2第12、13密码子基因突变情况,并分析其CRC病理特征、吸烟和饮酒情况与KRAS基因突变的相关性。结果 39.0%(32/82)患者KRAS基因突变,其中第12位密码子突变患者25例,占30.5%(25/82),第13位密码子突变患者7例,占8.5%(7/82); CRC组织KRAS基因突变与性别、肿瘤部位、肿瘤分期有关(P<0.05);与年龄、吸烟史、饮酒史、肿瘤分化程度、淋巴结转移于否、病理类型无关(P>0.05)。结论 CRC组织KRAS基因第12位密码子突变率高; KRAS基因突变多发生于女性患者、右半结肠、Ⅲ、Ⅳ期肿瘤患者。 Objective To investigate the correlation between KRAS gene mutations of CRC and pathological features,smoking and alcohol drinking. Methods The mutations of codon 12 and codon 13 of the KRAS gene exon 2 in cancer tissue of 82 patients with CRC were detected by ARMS-PCR method,and the correlation between CRC pathological features,smoking and alcohol drinking were analyzed. Results The KRAS gene mutations were found in 39.0%( 32/82) of the patients.There were 25 patients with mutations in the codon 12,accounting for 30.5%( 25/82),and 7 patients with codon mutations in the codon13,accounting for 8.5%( 7/82).The KRAS gene mutations in CRC tissues were associated with gender,tumor location,and tumor stages( P0.05) and not related to age,smoking history,alcohol drinking history,tumor differentiation,lymph node metastasis,and pathological types( P〉0.05).Conclusion The mutation rate of codon 12 in KRAS gene of CRC is high and KRAS gene mutations occur frequently in female patients,right colon,cancer patients with stage Ⅲ and Ⅳ.
作者 季硕超 刘淑真 郑德杰 陈悦 张盼 Ji Shuochao;Liu Shuzhen;Zheng Dejie;Chen Yue;Zhang Pan(Department of Internal Medicine,lFeifang Medical College,Weifang 261000,China;Department of Oncology,Weifang People's Hospital,Weifang 261000,China)
出处 《湖北民族学院学报(医学版)》 2018年第3期22-24,共3页 Journal of Hubei Minzu University(Medical Edition)
关键词 结直肠癌 KRAS基因 基因突变 CRC KRAS gene Gene mutations
  • 相关文献

参考文献4

二级参考文献29

  • 1Fang-Hua Li,Zhuang-Hua Li,Hui-Yan Luo,Miao-Zhen Qiu,Yu-Hong Li,Rui-Hua Xu,State Key Laboratory of Oncology in Southern China,Department of Medical Oncology,Sun YatSen University Cancer Center,Guangzhou 510060,Guangdong Province,China Fang-Hua Li,Department of Medical Oncology,Shengli Oil Field Central Hospital,Dongying 257034,Shandong Province,China Lin Shen,Department of GI Oncology,Peking University School of Oncology,Beijing Cancer Hospital and Institute,Beijing 100142,China Hui-Zhong Zhang,State Key Laboratory of Oncology in Southern China,Department of Pathology,Sun Yat-Sen University Cancer Center,Guangzhou 510060,Guangdong Province,China.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer[J].World Journal of Gastroenterology,2010,16(46):5881-5888. 被引量:9
  • 2高枫,唐卫中,李卫.中国人散发性大肠癌K-ras基因突变的研究[J].中华实验外科杂志,2005,22(1):65-67. 被引量:22
  • 3吴晓华,张莘,周文阔,易喜贤,吴涛,徐惠绵.p16和PTEN抑癌基因蛋白在结直肠腺癌组织中的表达及临床意义[J].中国肿瘤临床与康复,2006,13(1):11-13. 被引量:2
  • 4Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300. 被引量:1
  • 5De Roock W,Claes B,Bemasconi D,et al.Effects of KRAS,BRAF,NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer:a retrospective consortium analysis[J].Lancet Oncol,2010,11(8):753-762. 被引量:1
  • 6Souliferes D,Greer W,Magliocco AM,et al.KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies[J].Curr Oncol,2010,17 Suppl 1:S31-S40. 被引量:1
  • 7Van Cutsem E,Kdhne CH,Ldng I,et al.Cetuximab plus irinotecan,fluorouracil,and leucovorin as first-line treatment for metastatic colorectal cancer:updated analysis of overall survival according to tumor KRAS and BRAF mutation status[J].J Clin 0ncol,2011,29(15):2011-2019. 被引量:1
  • 8Zlobec I,Vuong T,Hayashi S,et al.A simple and reproducible scoring system for EGFR in colorectal cancer:application to prognosis and prediction of response to preoperative brachytherapy[J].Br J Cancer,2007,96(5):793-800. 被引量:1
  • 9Baldus SE,Schaefer KL,Engers R,et al.Prevalence and heterogeneity of KRAS,BRAF,and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases[J].Clin Cancer Res,2010,16(3):790-799. 被引量:1
  • 10Riely GJ,Ladanyi M.KRAS mutations:an old oncogene becomes a new predictive biomarker[J].J Mol Diagn,2008,10(6):493-495. 被引量:1

共引文献75

同被引文献18

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部